Drug transporters are critically important for the absorption, distribution, metabolism, and excretion (ADME) of many drugs and endogenous compounds. Therefore, disruption of these pathways by inhibition, induction, genetic polymorphisms, or disease can have profound effects on overall physiology, drug pharmacokinetics, drug efficacy, and toxicity. This white paper provides a review of changes in transporter function associated with acute and chronic disease states, describes regulatory pathways affecting transporter expression, and identifies opportunities to advance the field.

Additional Metadata
Persistent URL dx.doi.org/10.1002/cpt.1115, hdl.handle.net/1765/109578
Journal Clinical Pharmacology and Therapeutics
Evers, R. (Raymond), Piquette-Miller, M. (Micheline), Polli, J.W. (Joseph W.), Russel, F.G.M, Sprowl, J.A, Tohyama, K. (Kimio), … Brouwer, K.L.R. (2018). Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clinical Pharmacology and Therapeutics. doi:10.1002/cpt.1115